SLLN-15
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
For research use only. We do not sell to patients.
- CAS No.: 2403650-93-9
- Formula: C19H23N7Se2
- Molecular Weight:507.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner[1].
SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines[1].
Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TNBC cell lines BT-20 and MDA-MB-231.
-
Concentration:0, 1, 5, 10, 25 μM.
-
Incubation Time:24 hours.
-
Result:Inhibited the proliferation of two TNBC cell lines, BT-20 and MDA-MB-231.
-
Cell Line:TNBC cell lines (MDA-MB-231, BT-20, 4T1, MDA-MB-468), MCF-7 (ERBB2-), SKBR-3 (ERBB2+) and HEK293T.
-
Concentration:100 nM and 1000 nM.
-
Incubation Time:7 days.
-
Result:Equally inhibited the colony formation abilities of several breast cancer cell lines.
Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)[1]
-
Dosage:30mg/kg.
-
Administration:PO, 3 times a week for 40 days.
-
Result:Tumor allografts grew at a slower rate compared to control groups.
Significant inhibition of the number of lung metastases as visualized.
Chemical Information
-
CAS No. 2403650-93-9
-
Molecular Weight 507.35
-
Formula C19H23N7Se2
-
SMILES
C12=NC(NC3=CC=C(N4CC[Se]CC4)C=C3)=NC(N[C@@H]5C[Se]CC5)=C1N=CN2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SLLN-15 Related Classifications
HY-125465 Related Classifications
Powered by Bioz